Advertisement

Effective Medications for Treating Individuals with Autism Spectrum Disorder

  • Cristan FarmerEmail author
  • Jill Leon
  • Rebecca Hommer
Chapter
Part of the Pediatric School Psychology book series (PSP)

Abstract

More than half of all children diagnosed with autism spectrum disorder are prescribed psychotropic medication. This stands in contrast with the fact that there are no FDA-approved medications for the treatment of the core symptoms of ASD. ASD is commonly associated with challenging behaviors such as inattention, hyperactivity, irritability, aggression, and self-injury. Thus, pharmacologic treatment in children and adolescents with ASD is often targeted towards these associated problem behaviors. The purpose of this chapter is to highlight the efficacy and effectiveness of psychotropic medications used in the treatment of school-aged children with ASD. Both the intended and side effects of medication treatments commonly used to treat associated symptoms of ASD are reviewed. A set of references and web-based materials are provided to readers for additional information.

Keywords

ASD Irritability Inattention Aggression Neuroleptics Oxytocin Psychopharmacology 

References

  1. Aman, M. G., McDougle, C. J., Scahill, L., Handen, B., Arnold, L. E., Johnson, C., … Wagner, A. (2009). Medication and parent training in children with pervasive developmental disorders and serious behavior problems: Results from a randomized clinical trial. Journal of the American Academy of Child and Adolescent Psychiatry, 48(12), 1143–1154.CrossRefGoogle Scholar
  2. Arnold, L., Aman, M. G., Hollway, J., Hurt, E., Bates, B., Li, X., … Williams, C. (2012). Placebo-controlled pilot trial of mecamylamine for treatment of autism spectrum disorders. Journal of Child and Adolescent Psychopharmacology, 22(3), 198–205.CrossRefGoogle Scholar
  3. Autism Psychopharmacology. (2005). Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Archives of General Psychiatry, 62, 1266–1274.Google Scholar
  4. Benvenuto, A., Battan, B., Porfirio, M. C., & Curatolo, P. (2013). Pharmacotherapy of autism spectrum disorders. Brain and Development, 35(2), 119–127.CrossRefGoogle Scholar
  5. Bishop, S. L., Veenstra-VanderWeele, J., & Sanders, S. J. (2016). Attention finally being paid to girls at risk of autism. Journal of the American Academy of Child and Adolescent Psychiatry, 55(3), 159.CrossRefGoogle Scholar
  6. Buckley, A. W., Rodriguez, A. J., Jennison, K., Buckley, J., Thurm, A., Sato, S., & Swedo, S. (2010). Rapid eye movement sleep percentage in children with autism compared with children with developmental delay and typical development. Archives of Pediatrics & Adolescent Medicine, 164(11), 1032–1037.Google Scholar
  7. Chez, M., Buchanan, T., Becker, M., Kessler, J., Aimonovitch, M., & Mrazek, S. (2003). Donepezil hydrochloride: A double-blind study in autistic children. Journal of pediatric neurology, 1(2), 83–88.Google Scholar
  8. Cohen, S., Conduit, R., Lockley, S. W., Rajaratnam, S. M., & Cornish, K. M. (2014). The relationship between sleep and behavior in autism spectrum disorder (ASD): A review. Journal of Neurodevelopmental Disorders, 6(1), 44.CrossRefGoogle Scholar
  9. Centers for Disease Control and Prevention (CDC). (2009). Autism and developmental disabilities monitoring network surveillance year 2006. Principal investigators. Prevalence of autism spectrum disorders—Autism and developmental disabilities monitoring network, United States, 2006. MMWR Surveillance Summaries, 58(10), 1–20.Google Scholar
  10. Cortesi, F., Giannotti, F., Sebastiani, T., Panunzi, S., & Valente, D. (2012). Controlled-release melatonin, singly and combined with cognitive behavioural therapy, for persistent insomnia in children with autism spectrum disorders: A randomized placebo-controlled trial. Journal of Sleep Research, 21(6), 700–709.CrossRefGoogle Scholar
  11. Dadds, M. R., MacDonald, E., Cauchi, A., Williams, K., Levy, F., & Brennan, J. (2014). Nasal oxytocin for social deficits in childhood autism: A randomized controlled trial. Journal of Autism and Developmental Disorders, 44(3), 521–531.CrossRefGoogle Scholar
  12. Eichaar, G. M., Maisch, N. M., Augusto, L. M., & Wehring, H. J. (2006). Efficacy and safety of naltrexone use in pediatric patients with autistic disorder. Annals of Pharmacotherapy, 40(6), 1086–1095.CrossRefGoogle Scholar
  13. Feldman, H. M., Kolmen, B. K., & Gonzaga, A. M. (1999). Naltrexone and communication skills in young children with autism. Journal of the American Academy of Child and Adolescent Psychiatry, 38(5), 587–593.CrossRefGoogle Scholar
  14. Findling, R. L., Mankoski, R., Timko, K., Lears, K., McCartney, T., McQuade, R. D., … Sheehan, J. J. (2014). A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder. The Journal of Clinical Psychiatry, 75(1), 22–30.CrossRefGoogle Scholar
  15. Gordon, I., Vander Wyk, B. C., Bennett, R. H., Cordeaux, C., Lucas, M. V., Eilbott, J. A., … Pelphrey, K. A. (2013). Oxytocin enhances brain function in children with autism. Proceedings of the National Academy of Sciences, 110(52), 20953–20958.CrossRefGoogle Scholar
  16. Guastella, A. J., Einfeld, S. L., Gray, K. M., Rinehart, N. J., Tonge, B. J., Lambert, T. J., et al. (2010). Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biological Psychiatry, 67(7), 692–694.CrossRefGoogle Scholar
  17. Guastella, A. J., Gray, K. M., Rinehart, N. J., Alvares, G. A., Tonge, B. J., Hickie, I. B., … Einfeld, S. L. (2015). The effects of a course of intranasal oxytocin on social behaviors in youth diagnosed with autism spectrum disorders: A randomized controlled trial. Journal of Child Psychology and Psychiatry, 56(4), 444–452.CrossRefGoogle Scholar
  18. Handen, B., Aman, M. G., Arnold, L. E., Hyman, S. L., Tumuluru, R. V., Lecavalier, L., … Buchan-Page, K. A. (2015). Atomoxetine, parent training, and their combination in children with autism spectrum disorder and attention-deficit/hyperactivity disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 54(11), 905–915.CrossRefGoogle Scholar
  19. Handen, B., Sahl, R., & Hardan, A. Y. (2008). Guanfacine in children with autism and/or intellectual disabilities. Journal of Developmental and Behavioral Pediatrics, 29(4), 303–308.CrossRefGoogle Scholar
  20. Hardan, A. Y., Fung, L. K., Libove, R. A., Obukhanych, T. V., Nair, S., Herzenberg, L. A., … Tirouvanziam, R. (2012). A randomized controlled pilot trial of oral N-acetylcysteine in children with autism. Biological Psychiatry, 71(11), 956–961.CrossRefGoogle Scholar
  21. Harfterkamp, M., van de Loo-Neus, G., Minderaa, R. B., van der Gaag, R.-J., Escobar, R., Schacht, A., … Hoekstra, P. J. (2012). A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 51(7), 733–741.CrossRefGoogle Scholar
  22. Hellings, J. A., Weckbaugh, M., Nickel, E. J., Cain, S. E., Zarcone, J. R., Reese, R. M., … Schroeder, S. R. (2005). A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. Journal of Child & Adolescent Psychopharmacology, 15(4), 682–692.CrossRefGoogle Scholar
  23. Hollander, E., Chaplin, W., Soorya, L., Wasserman, S., Novotny, S., Rusoff, J., … Anagnostou, E. (2010). Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology, 35(4), 990–998.CrossRefGoogle Scholar
  24. Hollander, E., Phillips, A., Chaplin, W., Zagursky, K., Novotny, S., Wasserman, S., & Iyengar, R. (2005). A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology, 30(3), 582–589.Google Scholar
  25. Hollander, E., Soorya, L., Wasserman, S., Esposito, K., Chaplin, W., & Anagnostou, E. (2006). Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder. The International Journal of Neuropsychopharmacology, 9(2), 209–213.Google Scholar
  26. Howlin, P., & Magiati, I. (2017). Autism spectrum disorder. Current Opinion in Psychiatry, 30(2), 69–76.CrossRefGoogle Scholar
  27. Jahromi, L. B., Kasari, C. L., McCracken, J. T., Lee, L. S., Aman, M. G., McDougle, C. J., … Vitiello, B. (2009). Positive effects of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity. Journal of Autism and Developmental Disorders, 39(3), 395–404.CrossRefGoogle Scholar
  28. Ji, N. Y., & Findling, R. L. (2015). An update on pharmacotherapy for autism spectrum disorder in children and adolescents. Current Opinion in Psychiatry, 28(2), 91–101.PubMedGoogle Scholar
  29. Keen, D., Webster, A., & Ridley, G. (2016). How well are children with autism spectrum disorder doing academically at school? An overview of the literature. Autism, 20(3), 276–294.PubMedGoogle Scholar
  30. Kent, J. M., Hough, D., Singh, J., Karcher, K., & Pandina, G. (2013). An open-label extension study of the safety and efficacy of risperidone in children and adolescents with autistic disorder. Journal of Child and Adolescent Psychopharmacology, 23(10), 676–686.CrossRefGoogle Scholar
  31. King, B. H., Wright, D. M., Handen, B. L., Sikich, L., Zimmerman, A. W., McMahon, W., … & Hooper, S. R. (2001). Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 40(6), 658–665.Google Scholar
  32. King, B. H., Hollander, E., Sikich, L., McCracken, J. T., Scahill, L., Bregman, J. D., … Ritz, L. (2009). Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Archives of General Psychiatry, 66(6), 583–590.CrossRefGoogle Scholar
  33. Lemonnier, E., Degrez, C., Phelep, M., Tyzio, R., Josse, F., Grandgeorge, M., … Ben-Ari, Y. (2012). A randomised controlled trial of bumetanide in the treatment of autism in children. Translational Psychiatry, 2, e202.CrossRefGoogle Scholar
  34. Malow, B. A., Katz, T., Reynolds, A. M., Shui, A., Carno, M., Connolly, H. V., … Bennett, A. E. (2016). Sleep difficulties and medications in children with autism spectrum disorders: A registry study. Pediatrics, 137(Supplement 2), S98–S104.CrossRefGoogle Scholar
  35. Mandell, D. S., Morales, K. H., Marcus, S. C., Stahmer, A. C., Doshi, J., & Polsky, D. E. (2008). Psychotropic medication use among medicaid-enrolled children with autism spectrum disorders. Pediatrics, 121(3), e441–e448.Google Scholar
  36. Marcus, R. N., Owen, R., Kamen, L., Manos, G., McQuade, R. D., Carson, W. H., & Aman, M. G. (2009). A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 48(11), 1110–1119.Google Scholar
  37. McCracken, J. T. (2011). Pharmacotherapy for autism spectrum disorders. In D. G. Amaral, G. Dawson, & D. Geschwind (Eds.), Autism spectrum disorders (pp. 1309–1322). New York, NY: Oxford University Press.Google Scholar
  38. McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., … Research Units on Pediatric Psychopharmacology Autism, N. (2002). Risperidone in children with autism and serious behavioral problems. The New England Journal of Medicine, 347(5), 314–321.CrossRefGoogle Scholar
  39. McDougle, C. J., Scahill, L., Aman, M. G., McCracken, J. T., Tierney, E., Davies, M., … Vitiello, B. (2005). Risperidone for the core symptom domains of autism: Results from the study by the autism network of the research units on pediatric psychopharmacology. The American Journal of Psychiatry, 162(6), 1142–1148.CrossRefGoogle Scholar
  40. Nagaraj, R., Singhi, P., & Malhi, P. (2006). Risperidone in children with autism: Randomized, placebo-controlled. Double-Blind Study. Journal of child neurology, 21(6), 450–455.CrossRefGoogle Scholar
  41. Niederhofer, H., Staffen, W., & Mair, A. (2002). Galantamine may be effective in treating autistic disorder. BMJ (Clinical Research Ed.), 325(7377), 1422.CrossRefGoogle Scholar
  42. Owen, R., Sikich, L., Marcus, R. N., Corey-Lisle, P., Manos, G., McQuade, R. D., … Findling, R. L. (2009). Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics, 124(6), 1533–1540.CrossRefGoogle Scholar
  43. Pandina, G. J., Bossie, C. A., Youssef, E., Zhu, Y., & Dunbar, F. (2007). Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. Journal of Autism and Developmental Disorders, 37(2), 367–373.CrossRefGoogle Scholar
  44. Pearson, D. A., Santos, C. W., Aman, M. G., Arnold, L. E., Casat, C. D., Mansour, R., … Jerger, S. W. (2013). Effects of extended release methylphenidate treatment on ratings of attention-deficit/hyperactivity disorder (ADHD) and associated behavior in children with autism spectrum disorders and ADHD symptoms. Journal of Child and Adolescent Psychopharmacology, 23(5), 337–351.CrossRefGoogle Scholar
  45. Rezaei, V., Mohammadi, M.-R., Ghanizadeh, A., Sahraian, A., Tabrizi, M., Rezazadeh, S.-A., & Akhondzadeh, S. (2010). Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 34(7), 1269–1272.Google Scholar
  46. Robinson, E. B., St Pourcain, B., Anttila, V., Kosmicki, J. A., Bulik-Sullivan, B., Grove, J., … Ripke, S. (2016). Genetic risk for autism spectrum disorders and neuropsychiatric variation in the general population. Nature Genetics, 48(5), 552–555.Google Scholar
  47. Scahill, L., McCracken, J. T., King, B. H., Rockhill, C., Shah, B., Politte, L., … McDougle, C. J. (2015). Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder. The American Journal of Psychiatry, 172(12), 1197–1206.CrossRefGoogle Scholar
  48. Shea, S., Turgay, A., Carroll, A., Schulz, M., Orlik, H., Smith, I., & Dunbar, F. (2004). Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics, 114(5), e634–e641.Google Scholar
  49. Smith, I. C., Reichow, B., & Volkmar, F. R. (2015). The effects of DSM-5 criteria on number of individuals diagnosed with autism spectrum disorder: A systematic review. Journal of Autism and Developmental Disorders, 45(8), 2541–2552.CrossRefGoogle Scholar
  50. Spencer, D., Marshall, J., Post, B., Kulakodlu, M., Newschaffer, C., Dennen, T., … Jain, A. (2013). Psychotropic medication use and polypharmacy in children with autism spectrum disorders. Pediatrics, 132(5), 833–840.CrossRefGoogle Scholar
  51. Veenstra-VanderWeele, J., Cook, E. H., King, B. H., Zarevics, P., Cherubini, M., Walton-Bowen, K., … Carpenter, R. L. (2016). Arbaclofen in children and adolescents with autism spectrum disorder: A randomized, controlled, phase 2 trial. Neuropsychopharmacology.Google Scholar
  52. Volkmar, F., Siegel, M., Woodbury-Smith, M., King, B., McCracken, J., & State, M. (2014). Practice parameter for the assessment and treatment of children and adolescents with autism spectrum disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 53(2), 237–257.CrossRefGoogle Scholar
  53. Wasserman, S., Iyengar, R., Chaplin, W. F., Watner, D., Waldoks, S. E., Anagnostou, E., … Hollander, E. (2006). Levetiracetam versus placebo in childhood and adolescent autism: A double-blind placebo-controlled study. International Clinical Psychopharmacology, 21(6), 363–367.CrossRefGoogle Scholar
  54. Yatawara, C. J., Einfeld, S. L., Hickie, I. B., Davenport, T. A., & Guastella, A. J. (2016). The effect of oxytocin nasal spray on social interaction deficits observed in young children with autism: A randomized clinical crossover trial. Molecular Psychiatry, 21(9), 1225–1231.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Pediatrics & Developmental Neuroscience BranchNational Institute of Mental Health, National Institutes of HealthBethesdaUSA

Personalised recommendations